We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

By LabMedica International staff writers
Posted on 24 Jul 2024
Print article
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50% of DCIS patients may develop an invasive stage of cancer, yet identifying which tumors will progress is still a challenge due to unknown biomarkers. Current diagnostic practices include multiplexed staining or single-cell RNA sequencing to determine DCIS stages in tissue samples, but these methods are costly and not widely used. This has led to potential overtreatment of patients with DCIS. Now, a new artificial intelligence (AI) model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images.

The model developed by an interdisciplinary team of researchers from MIT (Cambridge, MA, USA) and ETH Zurich (Zurich, Switzerland) was trained and tested using one of the largest datasets of its kind that built because such tissue images are so easy to obtain. This AI model could potentially streamline the diagnosis process for simpler DCIS cases, reducing reliance on labor-intensive methods and allowing clinicians to focus more on ambiguous cases. Previously, the team found that a low-cost imaging technique called chromatin staining could deliver insights comparable to those from high-cost single-cell RNA sequencing. They hypothesized that combining this staining method with a sophisticated machine-learning model could yield detailed cancer stage information at a lower cost.

They compiled a dataset of 560 tissue sample images from 122 patients across three disease stages to train their AI model. This model learns to represent the state of each cell within an image to determine the cancer's stage. Recognizing that not all cells indicate cancer presence, the team engineered the model to create clusters of cells with similar states, identifying eight distinct states critical for diagnosing DCIS. Some states suggest a higher likelihood of invasive cancer. However, they learnt that knowing the proportion of each cell state was insufficient; understanding how these cells are organized within the tissue was also crucial. The model was enhanced to assess both the proportion and spatial arrangement of cell states, thereby significantly improving its accuracy. When compared to traditional pathologist evaluations, the model showed high concordance in many cases. For less definitive cases, the model provided insights into tissue sample features, like cell organization, which could aid pathologists in their diagnostics. This model’s versatility suggests potential applications beyond breast cancer to other cancers and neurodegenerative diseases, areas the researchers are currently exploring.

“We took the first step in understanding that we should be looking at the spatial organization of cells when diagnosing DCIS, and now we have developed a technique that is scalable,” said MIT’s Caroline Uhler. “From here, we really need a prospective study. Working with a hospital and getting this all the way to the clinic will be an important step forward.”

Related Links:
MIT
ETH Zurich

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.